The Brd4 Extraterminal Domain Confers Transcription Activation Independent of pTEFb by Recruiting Multiple Proteins, Including NSD3
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
Bromodomain protein 4 (Brd4) plays critical roles in development, cancer progression, and virus-host pathogenesis. To gain mechanistic insight into the various biological functions of Brd4, we performed a proteomic analysis to identify and characterize Brd4-associated cellular proteins. We found that the extraterminal (ET) domain, whose function has to date not been determined, interacts with NSD3, JMJD6, CHD4, GLTSCR1, and ATAD5. These ET-domain interactions were also conserved for Brd2 and Brd3, the other human BET proteins tested. We demonstrated that GLTSCR1, NSD3, and JMJD6 impart a pTEFb-independent transcriptional activation function on Brd4. NSD3 as well as JMJD6 is recruited to regulated genes in a Brd4-dependent manner. Moreover, we found that depletion of Brd4 or NSD3 reduces H3K36 methylation, demonstrating that the Brd4/NSD3 complex regulates this specific histone modification. Our results indicate that the Brd4 ET domain through the recruitment of the specific effectors regulates transcriptional activity. In particular, we show that one of these effectors, NSD3, regulates transcription by modifying the chromatin microenvironment at Brd4 target genes. Our study thus identifies the ET domain as a second important transcriptional regulatory domain for Brd4 in addition to the carboxyl-terminal domain (CTD) that interacts with pTEFb.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“N-terminal bromodomains confer binding to acetylated histone H3 and H4 tails, while the C-terminal extraterminal domain interacts with chromatin modifying enzymes such as histone methyltransferase NSD3 (REF.119,120).”
From Structure and function of retroviral integrase (2022) · cites this paper as [120]
Citations
Cites
High-Resolution Profiling of Histone Methylations in the Human Genome
Barski, A., Cuddapah, S., Cui, K., Roh, T.-Y., Schones, D. E., Wang, Z., Wei, G., Chepelev, I., & Zhao, K. (2007) · Cell · doi:10.1016/j.cell.2007.05.009 · Cited by 6,845 · cited 1×
“H3K36me3 levels were higher within the coding region, peaking at the 3 end, than at the promoter in accordance with published findings (2).”
ResultDefining the Human Deubiquitinating Enzyme Interaction Landscape
Sowa, M. E., Bennett, E. J., Gygi, S. P., & Harper, J. W. (2009) · Cell · doi:10.1016/j.cell.2009.04.042 · Cited by 1,512
Self-citationCarrozza, M. J., Li, B., Florens, L., Suganuma, T., Swanson, S. K., Lee, K. K., Shia, W.-J., Anderson, S., Yates, J., Washburn, M. P., et al. (2005) · Cell · doi:10.1016/j.cell.2005.10.023 · Cited by 1,294 · cited 1×
“Studies ranging from yeast to humans suggest that methylated H3K36 is enriched in regions of active transcription and is linked to transcriptional elongation and productive transcription within coding regions (5, 48, 49, 53).”
BackgroundJang, M. K., Mochizuki, K., Zhou, M., Jeong, H.-S., Brady, J. N., & Ozato, K. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.06.027 · Cited by 1,291 · cited 3×
“Many different BET family members, including the yeast bdf1/bdf2, Drosophila fs(1)h, and the mammalian Brd2, Brd3, and Brd4 proteins, have been implicated in transcription regulation (11, 13, 24, 27, 32).”
BackgroundRecruitment of P-TEFb for Stimulation of Transcriptional Elongation by the Bromodomain Protein Brd4
Yang, Z., Yik, J. H. N., Chen, R., He, N., Jang, M. K., Ozato, K., & Zhou, Q. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.06.029 · Cited by 1,138 · cited 2×
“However, only the CTD, present solely in Brd4 and fs(1)h, has been rigorously documented to regulate transcription through its interaction with pTEFb (4, 24, 56).”
BackgroundXue, Y., Wong, J., Moreno, G. T., Young, M. K., Côté, J., & Wang, W. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80299-3 · Cited by 985 · cited 1×
“CHD4 was observed to interact with components of the NuRD corepressor complex also as predicted previously (54).”
BackgroundJMJD6 Is a Histone Arginine Demethylase
Chang, B., Chen, Y., Zhao, Y., & Bruick, R. K. (2007) · Science · doi:10.1126/science.1145801 · Cited by 745 · cited 1×
“It was initially reported to be a histone arginine demethylase, responsible for H3R2me and H4R3me modifications (6).”
BackgroundControl of Inducible Gene Expression by Signal-Dependent Transcriptional Elongation
Hargreaves, D. C., Horng, T., & Medzhitov, R. (2009) · Cell · doi:10.1016/j.cell.2009.05.047 · Cited by 644 · cited 2×
“A recent study demonstrates that transcription of primary responsive genes in stimulated macrophages is dependent on Brd4 and is linked to production of mature spliced transcripts (19).”
BackgroundBRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma.
French, C. A., Miyoshi, I., Kubonishi, I., Grier, H. E., Pérez‐Atayde, A. R., & Fletcher, J. A. (2003) · PubMed · Cited by 501
The human Mi-2/NuRD complex and gene regulation
Denslow, S. A., & Wade, P. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210611 · Cited by 478 · cited 1×
“Notably, evidence suggests that it is involved in repression of genes that are regulated by estrogen receptor (12).”
Background
Research works printed but not linked: 2
- Denis G. V., 2000, Cell Growth Differ, 11, 417
- French C. A., 2003, Cancer Res, 63, 304
Cited by
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.036 · Cited by 2,961
“BRD4 is known to interact with Mediator and P-TEFb and to be involved in the control of transcriptional elongation by RNAPol II (Conaway and Conaway, 2011; Dawson et al., 2011; Jang et al., 2005; Krueger et al., 2010; Rahman et al., 2011; Yang et al., 2005).”
BackgroundBET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Delmore, J. E., Issa, G. C., Lemieux, M. E., Rahl, P. B., Shi, J., Jacobs, H. M., Kastritis, E., Gilpatrick, T., Paranal, R. M., Qi, J., et al. (2011) · Cell · doi:10.1016/j.cell.2011.08.017 · Cited by 2,813
“Your story matters.”
Writing, erasing and reading histone lysine methylations
Hyun, K., Jeon, J., Park, K., & Kim, J. (2017) · Experimental & Molecular Medicine · doi:10.1038/emm.2017.11 · Cited by 1,250
Understanding the language of Lys36 methylation at histone H3
Wagner, E. J., & Carpenter, P. B. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3274 · Cited by 936
The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition
Shi, J., & Vakoc, C. R. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.05.016 · Cited by 878
Miller, D. M., Thomas, S. D., Islam, A., Muench, D., & Sedoris, K. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0977 · Cited by 847
“and activate transcription by increasing the concentration of attracted transcriptional activators (85, 86).”
BET domain co-regulators in obesity, inflammation and cancer
Belkina, A. C., & Denis, G. V. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3256 · Cited by 711
BRD4 and Cancer: going beyond transcriptional regulation
Donati, B., Lorenzini, E., & Ciarrocchi, A. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0915-9 · Cited by 708
“It has been shown that the ET domain of BRD4 is involved in transcriptional regulation by interacting with histone modifiers including the arginine demethylase JMJD6 [36], the lysine methyltransferase NSD3 and the nucleosome remodeling enzymes SWIF/SNF and CDH4 [37].”
BackgroundTranscriptional plasticity promotes primary and acquired resistance to BET inhibition
Rathert, P., Roth, M., Neumann, T., Muerdter, F., Roe, J.-S., Muhar, M., Deswal, S., Cerny-Reiterer, S., Peter, B., Jude, J., et al. (2015) · Nature · doi:10.1038/nature14898 · Cited by 499
Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation
Shi, J., Whyte, W. A., Zepeda-Mendoza, C. J., Milazzo, J. P., Shen, C., Roe, J.-S., Minder, J. L., Mercan, F., Wang, E., Eckersley-Maslin, M. A., et al. (2013) · Genes & Development · doi:10.1101/gad.232710.113 · Cited by 463
“Prior proteomic studies found an association between SWI/SNF subunits and BET proteins (Denis et al. 2006; Dawson et al. 2011; Rahman et al. 2011), which we also have confirmed and found to be mediated by the ET domain of Brd4 (Supplemental Fig.”
BackgroundEpigenetic mechanisms in neurological disease
Jakovcevski, M., & Akbarian, S. (2012) · Nature Medicine · doi:10.1038/nm.2828 · Cited by 450
Born to run: control of transcription elongation by RNA polymerase II
Chen, F. X., Smith, E. R., & Shilatifard, A. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0010-5 · Cited by 447
Brd4 and JMJD6-Associated Anti-Pause Enhancers in Regulation of Transcriptional Pause Release
Liu, W., Ma, Q., Wong, K., Li, W., Ohgi, K., Zhang, J., Aggarwal, A. K., & Rosenfeld, M. G. (2013) · Cell · doi:10.1016/j.cell.2013.10.056 · Cited by 406
“Cell 155, 1581–1595, De regulated by JMJD6 and Brd4 (data not shown), may function for a distinct cohort of genes, based on binding on either promoter regions or distal enhancers (Rahman et al., 2011).”
BackgroundResultInfluentialTranscriptional Dependencies in Diffuse Intrinsic Pontine Glioma
Nagaraja, S., Vitanza, N. A., Woo, P. J., Taylor, K. R., Liu, F., Zhang, L., Li, M., Meng, W., Ponnuswami, A., Sun, W., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.03.011 · Cited by 396
“…et al., 2011; Zuber et al., 2011; Coudé et al., 2015; Picaud et al., 2015; Sengupta et al., 2015a, 2015b; Shahbazi et al., 2016; Zhang et al., 2016; Bid et al., 2016), a key activator of RNAPII transcription at active chromatin marks (Jang et al., 2005; LeRoy et al., 2008; Rahman et al., 2011).”
BackgroundInfluentialDevaiah, B. N., Lewis, B. A., Cherman, N., Hewitt, M. C., Albrecht, B. K., Robey, P. G., Ozato, K., Sims, R. J., & Singer, D. S. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1120422109 · Cited by 378
BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia
Ott, C. J., Kopp, N., Bird, L., Paranal, R. M., Qi, J., Bowman, T., Rodig, S. J., Kung, A. L., Bradner, J. E., & Weinstock, D. M. (2012) · Blood · doi:10.1182/blood-2012-02-413021 · Cited by 374
“A major function of the BET bromodomain BRD4 is the recognition of acetylated histones found in transcriptionally active regions of chromatin, which promotes the recruitment of transcriptional activators (15).”
BackgroundBET inhibitors: a novel epigenetic approach
Doroshow, D. B., Eder, J. P., & LoRusso, P. M. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx157 · Cited by 367
Phospho Switch Triggers Brd4 Chromatin Binding and Activator Recruitment for Gene-Specific Targeting
Wu, S.-Y., Lee, A.-Y., Lai, H.-T., Zhang, H., & Chiang, C.-M. (2013) · Molecular Cell · doi:10.1016/j.molcel.2012.12.006 · Cited by 347
“M PIM2, and DCPS whose transcripts were decreased in Brd4knockdown C-33A cells (Rahman et al., 2011), also showed diminished RNA (Figure 7E) with reduced Brd4 occupancy when known Brd4-binding sites were analyzed (Figure 7F).”
The Ubiquitin Ligase FBXW7 Modulates Leukemia-Initiating Cell Activity by Regulating MYC Stability
King, B., Trimarchi, T., Reavie, L., Xu, L., Mullenders, J., Ntziachristos, P., Aranda-Orgilles, B., Perez-Garcia, A., Shi, J., Vakoc, C., et al. (2013) · Cell · doi:10.1016/j.cell.2013.05.041 · Cited by 347
Taniguchi, Y. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17111849 · Cited by 336
The bromodomain protein Brd4 insulates chromatin from DNA damage signalling
Floyd, S. R., Pacold, M. E., Huang, Q., Clarke, S. M., Lam, F. C., Cannell, I. G., Bryson, B. D., Rameseder, J., Lee, M. J., Blake, E. J., et al. (2013) · Nature · doi:10.1038/nature12147 · Cited by 329
SET for life: biochemical activities and biological functions of SET domain-containing proteins
Herz, H.-M., Garruss, A., & Shilatifard, A. (2013) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2013.09.004 · Cited by 314
Drug Discovery Targeting Bromodomain-Containing Protein 4
Liu, Z., Wang, P., Chen, H., Wold, E. A., Tian, B., Brasier, A. R., & Zhou, J. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01761 · Cited by 303
Dynamic phosphorylation patterns of RNA polymerase II CTD during transcription
Heidemann, M., Hintermair, C., Voß, K., & Eick, D. (2013) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2012.08.013 · Cited by 299
Liquid–liquid phase separation in tumor biology
Tong, X., Tang, R., Xu, J., Wang, W., Zhao, Y., Yu, X., & Shi, S. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01076-x · Cited by 252
“The intervention of MM tumor cell proliferation with the BET-bromodomain inhibitor JQ1 causes a specific reduction in BRD4 at SEs, which results in disruption of MYC transcription elongation.(193,194) Moreover, BRD4 knockdown can induce cell apoptosis and inhibit the growth of MYCN (a member of the MYC family)-amplifi…”
BackgroundBromodomain biology and drug discovery
Zaware, N., & Zhou, M.-M. (2019) · Nature Structural & Molecular Biology · doi:10.1038/s41594-019-0309-8 · Cited by 240
Alqahtani, A., Choucair, K., Ashraf, M., Hammouda, D. M., Alloghbi, A., Khan, T., Senzer, N., & Nemunaitis, J. (2019) · Future Science OA · doi:10.4155/fsoa-2018-0115 · Cited by 240
Bromodomain and extraterminal (BET) proteins: biological functions, diseases and targeted therapy
Wang, Z.-Q., Zhang, Z.-C., Wu, Y.-Y., Pi, Y.-N., Lou, S.-H., Liu, T.-B., Lou, G., & Yang, C. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01647-6 · Cited by 216
“28,68 The role of BRD4 in the appropriate activation of that nonhomologous end-joined pathway is of signi fi cant importance.”
BackgroundNSD3–NUT Fusion Oncoprotein in NUT Midline Carcinoma: Implications for a Novel Oncogenic Mechanism
French, C. A., Rahman, S., Walsh, E. M., Kühnle, S., Grayson, A. R., Lemieux, M. E., Grunfeld, N., Rubin, B. P., Antonescu, C. R., Zhang, S., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0014 · Cited by 243
“NSD3 has been reported to regulate H3K36 methylation and thereby active gene expression (8, 26).”
BackgroundInfluentialSelf-citationClinical trials for BET inhibitors run ahead of the science
Andrieu, G., Belkina, A. C., & Denis, G. V. (2016) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2016.06.004 · Cited by 247
“Institutional review boards that oversee these studies should require monitoring for spikes in blood levels of HIV, human papilloma virus [25,26] or other BRD2- [27,28] or BRD4-regulated viruses [29] that might arise as adverse events in BET inhibitor trials.”
BackgroundChau, N. G., Ma, C., Danga, K., Al-Sayegh, H., Nardi, V., Barrette, R., Lathan, C. S., DuBois, S. G., Haddad, R. I., Shapiro, G. I., et al. (2020) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkz094 · Cited by 231
Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery
Fu, L.-L., Tian, M., Li, X., Li, J.-J., Huang, J., Ouyang, L., Zhang, Y., & Liu, B. (2015) · Oncotarget · doi:10.18632/oncotarget.3551 · Cited by 221
“com/oncotarget histone methyltransferase; JMJD6, a histone arginine demethylase; and CHD4, a catalytic component of the NuRD nucleosome remodeling complex [28].”
BackgroundEmber, S. W. J., Zhu, J.-Y., Olesen, S. H., Martin, M. P., Becker, A., Berndt, N., Georg, G. I., & Schönbrunn, E. (2014) · ACS Chemical Biology · doi:10.1021/cb500072z · Cited by 221
Alpsoy, A., & Dykhuizen, E. C. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.001065 · Cited by 227
“GLTSCR1 has also been identified in a proteomics study of BRD4-associating factors (32), as reflected by the recent change in HUGO gene name from GLTSCR1 to BICRA for BRD4-Interacting Chromatin Remodeling Complex Associated protein.”
BackgroundNUT Carcinoma: Clinicopathologic features, pathogenesis, and treatment
French, C. A. (2018) · Pathology International · doi:10.1111/pin.12727 · Cited by 210
Wang, X., Wang, S., Troisi, E. C., Howard, T. P., Haswell, J. R., Wolf, B. K., Hawk, W. H., Ramos, P., Oberlick, E. M., Tzvetkov, E. P., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09891-7 · Cited by 212
Gatchalian, J., Malik, S., Ho, J., Lee, D.-S., Kelso, T. W. R., Shokhirev, M. N., Dixon, J. R., & Hargreaves, D. C. (2018) · Nature Communications · doi:10.1038/s41467-018-07528-9 · Cited by 213
The Role of Nuclear Receptor–Binding SET Domain Family Histone Lysine Methyltransferases in Cancer
Bennett, R. L., Swaroop, A., Troche, C., & Licht, J. D. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026708 · Cited by 196
“NSD3 can bind the ET domain of BET proteins and associates with BRD4 in nuclear lysates (Rahman et al. 2011; French et al. 2014; Crowe et al. 2016).”
BackgroundChromatin Contributions to the Regulation of Innate Immunity
Smale, S. T., Tarakhovsky, A., & Natoli, G. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101303 · Cited by 200
White, E. A., Sowa, M. E., Tan, M. J. A., Jeudy, S., Hayes, S. D., Santha, S., Münger, K., Harper, J. W., & Howley, P. M. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1116776109 · Cited by 198
Self-citationAlekseyenko, A. A., Walsh, E. M., Wang, X., Grayson, A. R., Hsi, P. T., Kharchenko, P. V., Kuroda, M. I., & French, C. A. (2015) · Genes & Development · doi:10.1101/gad.267583.115 · Cited by 198
“Identification of the Mediator subunit MED24 as a BRD4-NUT target gene (Table 1) suggested an additional positive reinforcement loop for BRD4-NUT oncogenesis, as Mediator is known to interact physically with BRD4 (Jiang et al. 1998; Houzelstein et al. 2002; Dawson et al. 2011; Rahman et al. 2011).”
Place your BETs: the therapeutic potential of bromodomains
Prinjha, R. K., Witherington, J., & Lee, K. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.12.002 · Cited by 197
Opposing Functions of BRD4 Isoforms in Breast Cancer
Wu, S.-Y., Lee, C.-F., Lai, H.-T., Yu, C.-T., Lee, J.-E., Zuo, H., Tsai, S. Y., Tsai, M.-J., Ge, K., Wan, Y., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.04.034 · Cited by 192
“Besides BD1 and BD2, the molecular action of BRD4 also depends on the conserved ET domain, the CK2-phosphorylated region, and a unique C-terminal motif (CTM, not found in BRD2 and BRD3) that serve as interaction platforms for recruitment of various chromatin and/or transcriptional regulators (Wu and Chiang, 2007; Rahm…”
BackgroundThe Role of Bromodomain Proteins in Regulating Gene Expression
Josling, G. A., Selvarajah, S. A., Petter, M., & Duffy, M. F. (2012) · Genes · doi:10.3390/genes3020320 · Cited by 175
“Brd4 (also known as MCAP and Hunk1) has a similar structure to Brd2, but as well as having an extraterminal domain it has an additional C-terminal motif which is also involved in interacting with other proteins [137].”
BackgroundTargeting Cancer Cells with BET Bromodomain Inhibitors
Xu, Y., & Vakoc, C. R. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026674 · Cited by 180
“The ET domain interacts with several different cofactors, including the demethylase protein JMJD6, the methyltransferase/adaptor protein NSD3, and the chromatin remodeling ATPases CHD4 and BRG1 (Rahman et al. 2011; Shen et al. 2015).”
BackgroundInteractome Rewiring Following Pharmacological Targeting of BET Bromodomains
Lambert, J.-P., Picaud, S., Fujisawa, T., Hou, H., Savitsky, P., Uusküla-Reimand, L., Gupta, G. D., Abdouni, H., Lin, Z.-Y., Tucholska, M., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2018.11.006 · Cited by 174
“, 2008; Figure S4A) previously reported to mediate diverse protein interactions (Konuma et al., 2017; Rahman et al., 2011; Sansam et al., 2018; Zhang et al., 2016) and to associate with viral peptides (Crowe et al.”
BackgroundBromodomain-Containing Protein 4: The Epigenetic Origin of Pulmonary Arterial Hypertension
Meloche, J., Potus, F., Vaillancourt, M., Bourgeois, A., Johnson, I., Deschamps, L., Chabot, S., Ruffenach, G., Henry, S., Breuils-Bonnet, S., et al. (2015) · Circulation Research · doi:10.1161/circresaha.115.307004 · Cited by 183
Enhancers in disease: molecular basis and emerging treatment strategies
Claringbould, A., & Zaugg, J. B. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2021.07.012 · Cited by 181
Bandukwala, H. S., Gagnon, J., Togher, S., Greenbaum, J. A., Lamperti, E. D., Parr, N. J., Molesworth, A. M. H., Smithers, N., Lee, K., Witherington, J., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1212264109 · Cited by 181
“have demonstrated that the conserved extraterminal domain of all three BET proteins, BRD2, BRD3, and BRD4, associates with several chromatin-modifying factors (29), which include the H3K36 methyltransferase NSD3 (30); ATAD5, a replication factor involved in the ATM/ATR-mediated DNA damage response (31, 32); CHD4, a co…”
BackgroundRole of MYC in medulloblastoma
Roussel, M. F., & Robinson, G. W. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014308 · Cited by 180
“BRD4 is recruited to acetylated histones to stimulate transcriptional elongation and modify chromatin-regulating complexes (Rahman et al. 2011).”
BackgroundZawistowski, J. S., Bevill, S. M., Goulet, D. R., Stuhlmiller, T. J., Beltran, A. S., Olivares-Quintero, J. F., Singh, D., Sciaky, N., Parker, J. S., Rashid, N. U., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0653 · Cited by 180
“The extraterminal (ET) domain of BRD4 interacts with NSD3, an H3K36me3 histone methyltransferase, as well as with JMJD6, a JMJ-C family demethylase—both of which are components of P-TEFb–associated transcriptional regulatory complexes (48, 49).”
BackgroundMitotic bookmarking by transcription factors
Kadauke, S., & Blobel, G. A. (2013) · Epigenetics & Chromatin · doi:10.1186/1756-8935-6-6 · Cited by 167
“Potential mechanisms by which BET family proteins act to promote rapid transcriptional reactivation include recruitment of a variety of transcription complexes including P-TEFb, or possibly its intrinsic RNA polymerase 2 kinase activity [23,24,56,57].”
BackgroundLong-range enhancer activity determines Myc sensitivity to Notch inhibitors in T cell leukemia
Yashiro-Ohtani, Y., Wang, H., Zang, C., Arnett, K. L., Bailis, W., Ho, Y., Knoechel, B., Lanauze, C., Louis, L., Forsyth, K. S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1407079111 · Cited by 166
“Finally, because NTCs (22) and Brd4 (23) appear to regulate transcription by recruiting different multiprotein complexes and therefore might be expected to complement one another, it is unclear how high levels of activated Notch lower the requirement for Brd4, a conclusion drawn from both drug-sensitivity and shRNA-kn…”
BackgroundTargeting BET Bromodomains for Cancer Treatment
Jung, M., Gelato, K. A., Fernández-Montalván, A., Siegel, S., & Haendler, B. (2015) · Epigenomics · doi:10.2217/epi.14.91 · Cited by 163
Jung, M., Philpott, M., Müller, S., Schulze, J., Badock, V., Eberspächer, U., Moosmayer, D., Bader, B., Schmees, N., Fernández-Montalván, A., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.523019 · Cited by 155
BET Family Protein BRD4: An Emerging Actor in NFκB Signaling in Inflammation and Cancer
Hajmirza, A., Emadali, A., Gauthier, A., Casasnovas, O., Gressin, R., & Callanan, M. B. (2018) · Biomedicines · doi:10.3390/biomedicines6010016 · Cited by 173
“The extra-terminal (ET) domain is involved in transcriptional regulation through interactions with histone modifiers such as JMJD6 (jmjC domain-containing protein 6), an arginine demethylase, and NSD3, a lysine methyltransferase [9,10].”
BackgroundLam, F. C., Kong, Y. W., Huang, Q., Vu‐Han, T., Maffa, A., Kasper, E. M., & Yaffe, M. B. (2020) · Nature Communications · doi:10.1038/s41467-020-17503-y · Cited by 168
Small-molecule inhibitors of the Myc oncoprotein
Fletcher, S., & Prochownik, E. V. (2015) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.03.005 · Cited by 152
“The finding that DNA-boundMyc–Max heterodimers associate with pTEFb and relieve promoter proximal pausing, that this is associated with changes in the histone acetylation profile of bound genes and that KAc side chains are recognized by BET subfamily members (BRD2, BRD3, BRD4 and BRDT) provided reason to suspect that…”
NSD3-Short Is an Adaptor Protein that Couples BRD4 to the CHD8 Chromatin Remodeler
Shen, C., Ipsaro, J. J., Shi, J., Milazzo, J. P., Wang, E., Roe, J.-S., Suzuki, Y., Pappin, D. J., Joshua-Tor, L., & Vakoc, C. R. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.10.033 · Cited by 152
“To examine the molecular function of the BRD4 ET domain in AML, we measured the sensitivity of RN2 cells to short hairpin RNA (shRNA)-based targeting of known ET-associated proteins GLTSCR1, JMJD6, and NSD3 (Liu et al., 2013; Rahman et al., 2011).”
InfluentialSun, Y., Han, J., Wang, Z., Li, X., Sun, Y., & Hu, Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.621093 · Cited by 141
“BRD4 can recruit the PTEFb complex, JMJD6 (a histone arginine demethylase), NSD3 (a histone methyl transferase), P300 (acetyl transferase), and CHD4 (the catalytic subunit of the NuRD chromatin remodeler) (Taniguchi, 2016).”
BackgroundBET Bromodomain Inhibition Releases the Mediator Complex from Select cis-Regulatory Elements
Bhagwat, A. S., Roe, J.-S., Mok, B. Y. L., Hohmann, A. F., Shi, J., & Vakoc, C. R. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.03.054 · Cited by 158
Beating the odds: BETs in disease
Wang, C., & Filippakopoulos, P. (2015) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.06.002 · Cited by 170
BET Epigenetic Reader Proteins in Cardiovascular Transcriptional Programs
Borck, P. C., Guo, L., & Plutzky, J. (2020) · Circulation Research · doi:10.1161/circresaha.120.315929 · Cited by 169
Super-enhancer function and its application in cancer targeted therapy
Tang, F., Yang, Z., Tan, Y., & Li, Y. (2020) · npj Precision Oncology · doi:10.1038/s41698-020-0108-z · Cited by 159
Diverse epigenetic strategies interact to control epidermal differentiation
Mulder, K. W., Wang, X., Escriu, C., Ito, Y., Schwarz, R. F., Gillis, J., Sirokmány, G., Donati, G., Uribe‐Lewis, S., Pavlidis, P., et al. (2012) · Nature Cell Biology · doi:10.1038/ncb2520 · Cited by 157
The developmental origin of brain tumours: a cellular and molecular framework
Azzarelli, R., Simons, B. D., & Philpott, A. (2018) · Development · doi:10.1242/dev.162693 · Cited by 135
“This leads to the accumulation of bromodomains and extra-terminal domain (BET) proteins, as well as more recruitment of the transcriptional cyclin-dependent kinase CDK7, which directs high levels of transcription (Larochelle et al., 2012; LeRoy et al., 2008; Rahman et al., 2011).”
BackgroundThe BET Protein BRD2 Cooperates with CTCF to Enforce Transcriptional and Architectural Boundaries
Hsu, S. C., Gilgenast, T. G., Bartman, C. R., Edwards, C. R., Stonestrom, A. J., Huang, P., Emerson, D. J., Evans, P., Werner, M. T., Keller, C. A., et al. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.02.027 · Cited by 143
“Previous reports suggested that BRD2, BRD3, and BRD4 bind to overlapping sets of transcriptional regulatory complexes (Dawson et al., 2011; Rahman et al., 2011) and exhibit significantly overlapping occupancy at active genes (Anders et al.”
BackgroundConrad, R. J., Fozouni, P., Thomas, S., Sy, H., Zhang, Q., Zhou, M.-M., & Ott, M. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.07.025 · Cited by 135
Alekseyenko, A. A., Walsh, E. M., Zee, B. M., Pakozdi, T., Hsi, P. T., Lemieux, M. E., Cin, P. D., Ince, T. A., Kharchenko, P. V., Kuroda, M. I., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1702086114 · Cited by 146
“S1B) include BRD2, BRD3, WHSC1L1, WHSC1, ATAD5, CCNT1, CREBBP, and EP300.”
BackgroundInfluentialMiller, T. C. R., Simon, B., Rybin, V., Grötsch, H., Curtet, S., Khochbin, S., Carlomagno, T., & Müller, C. W. (2016) · Nature Communications · doi:10.1038/ncomms13855 · Cited by 132
“22 Truncated H4(A15C) and H3(A25C)(for chimeric nucleosomes) were ligated to a peptide consisting of a His-tag, TEV-cleavage site and the H4 N-terminal sequence (1-14) and therefore could be purified using Ni-NTA agarose (Qiagen).”
MethodThe NSD Family of Protein Methyltransferases in Human Cancer
Vougiouklakis, T., Hamamoto, R., Nakamura, Y., & Saloura, V. (2015) · Epigenomics · doi:10.2217/epi.15.32 · Cited by 120
Özer, H. G., El‐Gamal, D., Powell, B., Hing, Z. A., Blachly, J. S., Harrington, B. K., Mitchell, S. R., Grieselhuber, N. R., Williams, K., Lai, T.-H., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0902 · Cited by 142
“Next we evaluated the long-term in vivo therapeutic effects of PLX51107 utilizing an adoptive transfer model (61, 63) in which leukemic cells from a Eμ-TCL1 mouse are engrafted into healthy wild-type (WT) recipients of the same background.”
BackgroundBromodomains and Their Pharmacological Inhibitors
Gallenkamp, D., Gelato, K. A., Haendler, B., & Weinmann, H. (2014) · ChemMedChem · doi:10.1002/cmdc.201300434 · Cited by 122
Bromodomain 4: a cellular Swiss army knife
Devaiah, B. N., Gégonne, A., & Singer, D. S. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.2ri0616-250r · Cited by 136
Stevens, T. M., Morlote, D. M., Xiu, J., Swensen, J. J., Brandwein‐Weber, M., Miettinen, M., Gatalica, Z., & Bridge, J. A. (2019) · Modern Pathology · doi:10.1038/s41379-019-0206-z · Cited by 127
Structure and function of retroviral integrase
Maertens, G. N., Engelman, A. N., & Cherepanov, P. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00586-9 · Cited by 124
Korb, E., Herre, M., Zucker-Scharff, I., Gresack, J. E., Allis, C. D., & Darnell, R. B. (2017) · Cell · doi:10.1016/j.cell.2017.07.033 · Cited by 134
“Fifth, Brd4 interacts with numerous other chromatin-associated FMRP targets and their family members such as Chd4, Nsd3, Jmjd5, and Chd8 (Rahman et al., 2011; Shen et al., 2015).”
Functional Analysis of the Replication Fork Proteome Identifies BET Proteins as PCNA Regulators
Wessel, S. R., Mohni, K. N., Luzwick, J. W., Dungrawala, H., & Cortez, D. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.051 · Cited by 126
“In agreement with our data, protein interaction screens previously suggested interactions between BRD2 and BRD4 with replication factor C subunits (Lambert et al., 2019; Maruyama et al., 2002; Rahman et al., 2011).”
Identification and functional characterization of transcriptional activators in human cells
Alerasool, N., Leng, H., Lin, Z.-Y., Gingras, A.-C., & Taipale, M. (2022) · Molecular Cell · doi:10.1016/j.molcel.2021.12.008 · Cited by 120
The Commonly Used PI3-Kinase Probe LY294002 Is an Inhibitor of BET Bromodomains
Dittmann, A., Werner, T., Chung, C.-W., Savitski, M. M., Fälth Savitski, M., Grandi, P., Hopf, C., Lindon, M., Neubauer, G., Prinjha, R. K., et al. (2014) · ACS Chemical Biology · doi:10.1021/cb400789e · Cited by 117
Bromodomain Histone Readers and Cancer
Jain, A. K., & Barton, M. C. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.11.020 · Cited by 123
Mechanisms and strategies of papillomavirus replication
McBride, A. A. (2017) · Biological Chemistry · doi:10.1515/hsz-2017-0113 · Cited by 116
Najafova, Z., Tirado-Magallanes, R., Subramaniam, M., Hossan, T., Schmídt, G., Nagarajan, S., Baumgart, S. J., Mishra, V. K., Bedi, U., Hesse, E., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw826 · Cited by 120
“Moreover, proteomic analyses revealed the ability of the ET domain of BRD4 to interact with other chromatinassociated proteins like NSD3 and JMJD6 (9,10).”
BackgroundTranscriptional Regulation by (Super)Enhancers: From Discovery to Mechanisms
Grosveld, F., van Staalduinen, J., & Stadhouders, R. (2021) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-122220-093818 · Cited by 115
The Functions of BET Proteins in Gene Transcription of Biology and Diseases
Cheung, K. L., Kim, C., & Zhou, M.-M. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.728777 · Cited by 109
Wu, X., Liu, D., Tao, D., Xiang, W., Xiao, X., Wang, M., Wang, L., Luo, G., Li, Y., Zeng, F., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0750 · Cited by 116
Hypertranscription and replication stress in cancer
Bowry, A., Kelly, R. D., & Petermann, E. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.04.006 · Cited by 119
HDAC11 suppresses the thermogenic program of adipose tissue via BRD2
Bagchi, R. A., Ferguson, B. S., Stratton, M. S., Hu, T., Cavasin, M. A., Sun, L., Lin, Y.-H., Liu, D., Londono, P., Song, K., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.120159 · Cited by 110
H3K36me3, message from chromatin to DNA damage repair
Sun, Z., Zhang, Y., Jia, J., Fang, Y., Tang, Y., Wu, H., & Fang, D. (2020) · Cell & Bioscience · doi:10.1186/s13578-020-0374-z · Cited by 109
Discovery of Chemical Inhibitors of Human Bromodomains
Zhang, G., Smith, S. G., & Zhou, M.-M. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00205 · Cited by 106
Miteva, Y. V., Budayeva, H. G., & Cristea, I. M. (2013) · Analytical Chemistry · doi:10.1021/ac3033257 · Cited by 105
Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines
Campbell, J., Ryan, C. J., Brough, R., Bajrami, I., Pemberton, H. N., Chong, I. Y., Costa-Cabral, S., Frankum, J., Gulati, A., Holme, H., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.02.023 · Cited by 101
“…in esophageal cancer models, we identified a significant association betweenmutation of the chromatin remodeling factor gene SMARCA4 and dependency upon the bromodomain protein BRD4 (p = 6 3 10 3; Figure 3F), previously identified as a protein interaction partner of SMARCA4 (Rahman et al., 2011).”
BackgroundInfluentialBET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications
To, K. K. W., Xing, E., Larue, R. C., & Li, P. (2023) · Molecules · doi:10.3390/molecules28073043 · Cited by 112
“Meanwhile, the ET domain of Brd4 is known to recruit other transcriptional activators including NSD3, JMJD6, and CHD4 to further promote gene transcription [18].”
BackgroundIdentification and Proteomic Analysis of Distinct UBE3A/E6AP Protein Complexes
Martínez-Noël, G., Galligan, J. T., Sowa, M. E., Arndt, V., Overton, T. M., Harper, J. W., & Howley, P. M. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.00201-12 · Cited by 97
“This technology has been successfully used to identify protein interactors among the hundreds of proteins typically identified in immunoprecipitation-MS experiments (5, 12, 72, 73, 95).”
MethodSelf-citationGao, W., Xiao, R.-Q., Zhang, W., Hu, Y., Peng, B., Li, W., He, Y., Shen, H., Ding, J., Huang, Q.-X., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.03.006 · Cited by 101
“Besides its function in transcriptional control, we and others have shown that JMJD6 also interacts with multiple splicing factors, and is involved in gene splicing control (Heim et al., 2014, Webby et al., Liu et al., 2013, Rahman et al., 2011, Yi et al., 2017).”
The oxygenase Jmjd6–a case study in conflicting assignments
Böttger, A., Islam, M. S., Chowdhury, R., Schofield, C. J., & Wolf, A. (2015) · Biochemical Journal · doi:10.1042/bj20150278 · Cited by 108
BET proteins: Biological functions and therapeutic interventions
Guo, J., Zheng, Q., & Peng, Y. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108354 · Cited by 98
Edwards, D. S., Maganti, R., Tanksley, J., Luo, J. D., Park, J. J. H., Balkanska-Sinclair, E., Ling, J., & Floyd, S. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108166 · Cited by 100
“Through its C-terminal domain (CTD) it is known to activate CDK9, the RNAPII-phosphorylating component of the positive transcription elongation factor, P-TEFb (Chen et al., 2014; Itzen et al., 2014; Jang et al., 2005; Kanno et al., 2014; Liu et al., 2013; Patel et al., 2013; Rahman et al., 2011; Winter et al., 2017; Z…”
InfluentialBiased Multicomponent Reactions to Develop Novel Bromodomain Inhibitors
McKeown, M. R., Shaw, D. L., Fu, H., Liu, S., Xu, X., Marineau, J., Huang, Y., Zhang, X., Buckley, D. L., Kadam, A., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501120z · Cited by 96
Small-Molecule Targeting of BET Proteins in Cancer
French, C. A. (2016) · Advances in cancer research · doi:10.1016/bs.acr.2016.04.001 · Cited by 92
“The ET domain also associates with ATP-dependent chromatin remodeling enzymes including the helicase, CHD4, and SMARCA4, a member of the SWI/SNF complex (Rahman et al., 2011).”
Background
Metadata
- Authors
- Rahman, S., Sowa, M. E., Ottinger, M., Smith, J. A., Shi, Y., Harper, J. W., & Howley, P. M.
- Affiliations
- Harvard University (US)
- Corresponding author
- Howley, Peter M.
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 2011-07-01
- Volume
- 31
- Issue
- 13
- Pages
- 2641-2652
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- PMC
- PMC3133372
- OpenAlex
- W2167732604
- Cited by
- 532
- References
- 60
- Citations by year
- 2026: 25 · 2025: 14 · 2024: 41 · 2023: 39 · 2022: 35 · 2021: 55 · 2020: 37 · 2019: 41 · 2018: 39 · 2017: 42 · 2016: 40 · 2015: 30 · 2014: 27 · 2013: 33 · 2012: 27
- FWCI
- 12.22
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Molecular and Cellular Biology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute on Aging (AG011085, R01AG011085)
- National Cancer Institute (T32CA009361, R01CA116720)
- National Institute of General Medical Sciences (GM054137, R01GM054137, R01GM070565)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- BRD4, NSD3, JMJD6, ATAD5, CHD4, H3K36 methylation, chromatin recruitment, BET proteins, BRD2, BRD3, protein-protein interaction, histone modifications
- MeSH terms
- Bromodomain Containing Proteins, Amino Acid Sequence, Cell Line, Chromosomal Proteins, Non-Histone, Humans, Molecular Sequence Data, Nuclear Proteins, Histone-Lysine N-Methyltransferase, Transcription Factors, Transcriptional Activation, Protein Structure, Tertiary, Cell Cycle Proteins, Tumor Suppressor Proteins, Positive Transcriptional Elongation Factor B, Jumonji Domain-Containing Histone Demethylases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.